Chapter 3 │ Page 107 References 1. Pannunzio, S., et al., Multimodality treatment in recurrent/metastatic squamous cell carcinoma of head and neck: current therapy, challenges, and future perspectives. Front Oncol, 2023. 13: p. 1288695. 2. Bruce E Brockstein, E.E.V., Treatment of metastatic and recurrent head and neck cancer. UpToDate, 2024. 3. So, W.K., et al., Quality-of-life among head and neck cancer survivors at one year after treatment--a systematic review. Eur J Cancer, 2012. 48(15): p. 2391-408. 4. Douglas, C., et al., Quality of Life Impacts Following Surgery for Advanced Head and Neck Cancer. World J Oncol, 2023. 14(2): p. 150-157. 5. Abel, E., et al., Long-Term Aspects of Quality of Life in Head and Neck Cancer Patients Treated With Intensity Modulated Radiation Therapy: A 5-Year Longitudinal Follow-up and Comparison with a Normal Population Cohort. Adv Radiat Oncol, 2020. 5(1): p. 101-110. 6. Harrington, K.J., et al., Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study. Journal of Clinical Oncology, 2022. 41(4): p. 790-802. 7. Bresadola, L., et al., Temporal evolution and inter-patient heterogeneity in primary and recurrent head and neck squamous cell carcinoma. BJC Reports, 2024. 2(1): p. 62. 8. Farah, C.S., Molecular landscape of head and neck cancer and implications for therapy. Ann Transl Med, 2021. 9(10): p. 915. 9. Burtness, B., et al., Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet, 2019. 394(10212): p. 1915-1928. 10. Perri, F., et al., Immune Response Against Head and Neck Cancer: Biological Mechanisms and Implication on Therapy. Translational Oncology, 2020. 13(2): p. 262274. 11. Meci, A., N. Goyal, and G. Slonimsky Mechanisms of Resistance and Therapeutic Perspectives in Immunotherapy for Advanced Head and Neck Cancers. Cancers, 2024. 16, DOI: 10.3390/cancers16040703. 12. Elmorsy, E.A., et al., Advances in understanding cisplatin-induced toxicity: Molecular mechanisms and protective strategies. European Journal of Pharmaceutical Sciences, 2024. 203: p. 106939. 13. Cavalieri, S., et al., Pre-treatment risk factors to predict early cisplatin-related nephrotoxicity in locally advanced head and neck cancer patients treated with chemoradiation: A single Institution experience. Oral Oncology, 2023. 146: p. 106579. 14. Wada, S., S. Kobayashi, and T. Tsunoda, Future prospects for cancer immunotherapy - Strategies for ine ective cancers. Hum Vaccin Immunother, 2022. 18(1): p. 2031699. 15. Mellman, I., et al., The cancer-immunity cycle: Indication, genotype, and immunotype. Immunity, 2023. 56(10): p. 2188-2205.
RkJQdWJsaXNoZXIy MTk4NDMw